GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X et al (2021) GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimers disease
8 Max Planck Institute for Metabolism Research, Center for Endocrinology, Diabetes and Preventive Medicine, University Hospital of Cologne, Center for Molecular Medicine Cologne, and 9 Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany
Growing recognition of the brands clinical effectiveness and extensive long-term safety profile is supporting prescription growth
Wegovy (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying, potentially exacerbating pre-existing gastric conditions Common gastrointestinal side effects include nausea (44%), vomiting (24%), dyspepsia, abdominal pain, and constipation Gastritis is not listed as a recognised adverse effect in the UK Summary of Product Characteristics Patients with severe gastrointestinal disease or history of peptic ulcer disease should discuss risks with their prescriber before starting treatment Seek urgent medical advice for severe abdominal pain, vomiting blood, black stools, or persistent symptoms that do not improve Table of Contents Can Wegovy Cause Gastritis
Riboflavin (vitamin B2)Riboflavin as a coenzyme has an important role in the production of energy from food